INTRODUCTION {#sec1-1}
============

We present a case of a previously overall healthy 42-year-old female nonsmoker diagnosed with nonsmall cell lung cancer (NSCLC) in July 2011. Primary tumor screening proved liver and mediastinal lymph node involvement as well as the presence of a solitary L3 bone metastasis (T4N3M1a). The patient initially benefited from single tyrosine kinase inhibitor (TKI) therapy from July 2011 to March 2012 followed by combined chemotherapy and TKI treatment from April 2012 to December 2012, achieving next to complete regression of lung, liver, and nodal metastases. The lumbar metastasis remained stationary. In January 2013, the patient started TKI-maintenance therapy and underwent stereotactic body radiotherapy in order to treat a remaining lung lesion in the left lower lobe. In late March 2013, the patient developed onset of headaches, nausea, balance issues, intermittent perioral numbness, and fatigue. A computed tomography (CT)-scan and a magnetic resonance imaging (MRI) revealed at least 20 small cerebral lesions as well as a 20 mm brainstem lesion located in the pons. The patient started oral steroid therapy and underwent whole brain radiotherapy (WBRT) in April 2013 with 4 Gy daily fractions over 5 consecutive days (4 Gy × 5). An MRI performed 3 months after WBRT (July 2013) demonstrated next to complete regression of all small lesions; the pontine metastasis displayed a significant volume reduction of about 20% (20--16 mm). By this particular time, the patient\'s clinical status had also improved, only exhibiting symptoms of mild fatigue. A second follow-up MRI was performed in October 2013. The images revealed a striking tumor volume increase of the pontine lesion (16 mm in July to 26 mm in October 2013) as well as significant amount of perifocal edema, extending into the left side of the midbrain and cerebellar peduncles. By this time, the patient was experiencing mild left-sided second branch trigeminal nerve territory numbness (BNI-FN-Scale 2) as well as fatigue (Karnofsky scale 90). Further, extracranial radiological screening revealed limited thoracic metastatic activity (left lower lobe); hence, deductively recursive partitioning analysis (RPA)-class 2 \[[Table 1](#T1){ref-type="table"}\]. The case was presented to Karolinska University Hospital\'s Gamma Knife Unit in November 2013. As microsurgery and further linear accelerator (LINAC)-based radiotherapy were earlier contraindicated, we resolved to treat the patient by means of gamma knife-based adaptive hypofractionated radiosurgery (AHR-GK). Treatment endpoints were set to achieve tumor volume reduction, avoid further neurological damage, prevent obstructive hydrocephalus, and limit the development of radiation-induced healthy tissue toxicity.

###### 

Radiation oncology therapy group RPA classes 1-3 for brain metastases
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RADIOSURGICAL ACCOUNT {#sec1-2}
=====================

The tumor had proven to be sensitive to prior WBRT and systemic treatment, and since microsurgery and further LINAC-based radiotherapy were earlier contraindicated, we resolved to treat the patient by means of AHR-GK. AHR-GK is an image-guided neurosurgical procedure aiming to dynamically treat larger brainstem lesions by means of nonhomogenously adjusted radiation doses within tumor boundaries in relation to ongoing tumor volume reduction through the course of radiotherapy. Sparing of healthy tissue while modifying dose delivery remains an important aspect of the treatment. In order to adapt radiation doses to expected morphological changes during the course of radiosurgery, a regimen was designed to deliver a total of three radiation treatments during the course of 6 days. Each fraction was to be delivered every 48 h. Optimal cranium fixation was achieved using the Leksell^®^ stereotactic frame preceding each treatment. In order to attain capital dynamic target definition, stereotactic MRI-based treatment plans were performed prior each treatment. No additional plan margins were required other than the gross tumor volume (GTV = GTV, planning target volume not required because of frame-based stereotactic conditions). A renewed clinical examination preceding treatment initiation (treatment number 1), showed some exacerbation of the left side facial numbness (BNI-FN-Scale 2--3), fluctuating body temperature, and tiredness (Karnofsky scale 80--90). Brainstem toxicity (By CTEP-US Cancer Institute standards) at first treatment was graded as 1--2 \[Tables [2](#T2){ref-type="table"}--[4](#T4){ref-type="table"}\].

###### 

Brainstem injury grading according to U.S. National Cancer Institute standards
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###### 

Performance status based on the karnofsky scale
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###### 

The barrow neurological institute facial numbness scale
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A strategic pretreatment planning was set upon previous MRI, past institutional experience, and vital patient data (tumor histopathological traits, tumor size, tumor localization, anatomical landmarks, previous response to intra- and extra-cranial radiation, radiobiological conditions due to prior WBRT and current knowledge on brainstem toxicity as well as clinical status by the time of radiosurgery). Institutional experience and world medical data show that larger metastases are likely to respond to physical dose regimens of 6--7 Gy given in 5 daily fractions (6--7 Gy × 5). An isoeffective regimen of three fractions was conceived using conventional linear-quadratic-model/biological equivalent dose estimates. Since the patient had previously been subjected to WBRT (physical dose regimen of 4 Gy\'s in five daily fractions = 4 Gy × 5), we had to apply a lower prescription dose to the margin in order to maximize healthy brainstem tissue sparing. Based on isoeffective estimations corresponding to prior WBRT (4 Gy × 5) and brainstem axis radiation tolerance data, we decided to set the prescription (marginal) dose between 6 and 7 Gy. To achieve best (maximal) dose distribution to target, the peripheral prescription dose was set at the 35% line. As a way to "monitor" dose dissipation to adjacent healthy tissues while increasing the prescription dose, treatment volumes to the 4 Gy isodose were to be kept as low and comparable as possible \[[Table 5](#T5){ref-type="table"}\]. As in all GK planning, we aimed for best possible target coverage, highest achievable selectivity (a ratio indicating how much adjacent healthy tissue is spared), and lowest gradient index (quality of dose falloff outside target) conditions would allow.\[[@ref15][@ref40]\]

###### 

Radiosurgical summary illustrating changes in gross tumor volume (GTV), 4^th^ ventricle width and 4 Gy - volume (in terms of treatment planning quality control). Minimum, maximum and mean doses to target (GTV) per fraction are given in Gray Units
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Before treatment start, the patient was thoroughly informed of the upcoming procedure, strategies, goals, and potential local adverse reactions. The patient was positive to treatment and started oral corticosteroid therapy (betamethasone) due to extensive preexisting edema.

By the 1^st^ day of treatment, the stereotactic MRI showed a slight volume progression of the brainstem metastasis; Leksell GammaPlan^®^ volumetric measurements estimated a target volume of 9, 27 cc. Fluid-attenuated inversion recovery and other T2-weighted-sequences exhibited a considerable amount of edema within the left pontine boundaries, tectum, and left cerebellar peduncle. A renewed assessment based on all present factors confirmed a peripheral dose of 6 Gy to the 35% isodose for the first treatment. "Hot spots" were circumscribed to the 12 Gy isodose covering areas with the strongest contrast enhancement \[[Figure 1](#F1){ref-type="fig"}\]. We also noticed an en passant 12 mm metastasis located in left occipital lobe; this metastasis was treated with a single dose of 21 Gy to the 50% isodose.

![LGP (Leksell GammaPlan®) snapshots reviewing treatment planning: hot spots defined within the 12 Gy isodose line (Green) covering strongest contrast enhancement (transverse, coronal and sagittal projections)](SNI-7-130-g006){#F1}

Because of logistics, the second fraction was delivered 3 days later (day 4); the second stereotactic MRI displayed no significant tumor reduction. There was somewhat less edema. The patient was still on steroids but showed no clinical improvement. We proceeded to deliver a second fraction of 6 Gy to the 35% isodose line.

The third and final treatment was given 2 days later (day 6). Its correspondent stereotactic MRI revealed an 18% volume decrement compared to the previous stereotactic MRI \[[Table 5](#T5){ref-type="table"}\]. The images also demonstrated a decrease in surrounding edema and reduced compression of the fourth ventricle. A supplementary clinical examination prior to the third (and last) radiosurgical treatment showed a substantial decrease in facial numbness, body temperature normalization, and considerable improvement in general strength (Karnofsky 100). Because of the above new conditions, we proceeded to increase the marginal prescription dose to 7 Gy to the 35% isodose line.

The patient remained on cortisone throughout her treatments. Steroids were rapidly de-escalated after surgery completion. Frame application 3 times a week was well tolerated by the patient.

OUTCOME {#sec1-3}
=======

Follow-up MRIs at one and 2.5 months after radiosurgery (follow-up MRI numbers 1 and 2) showed a tumor volume abatement of about 67% during the course of 8 weeks \[[Table 6](#T6){ref-type="table"}\]. The perifocal edema had almost resolved \[[Figure 2](#F2){ref-type="fig"}\]. Compression of the fourth ventricle was further reduced \[[Figure 2](#F2){ref-type="fig"} and [Table 6](#T6){ref-type="table"}\]. The occipital lesion had dramatically decreased by the second follow-up. The patient remained almost asymptomatic at the time of the first and second follow-up.

###### 

Follow up at one and two months after GK-SAHR: MRI and LGP - verified volumetric impact on target (GTV) and 4^th^ ventricle
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![(transverse and sagittal MRI projections) - From left to right: Stereotactic MRI by first day of treatment (a), Follow up MRI at 1 m (b), Follow up MRI at 2.5 m (c). Tumor size reduction and subsequent normalization of 4th ventricle width. Blue line delineates original tumor volume (GTV)](SNI-7-130-g008){#F2}

Follow-up MRI at 4.5 and 5.5 months (follow-up MRI 4 and 5) showed the progression of tumor size, with edema extending into the midbrain, pons, and left cerebellar peduncle. A local radiation adverse effect was initially suspected and indeed expected \[Figure [3](#F3){ref-type="fig"} and [4](#F4){ref-type="fig"}\]. Since sadiation necrosis and recurrent brain tumor can manifest with similar symptoms and may be indistinguishable on MRI, fluorodeoxyglucose-positron emission tomography (FDG-PET) has been proposed as a diagnostic alternative, particularly when co-registered with MRI. For brain metastases with MRI co-registration, FDG-PET has a sensitivity of 86% and specificity of 80%.\[[@ref6][@ref51][@ref53]\]

![local tumor volume increase 5.5 months after treatment, suspected local adverse radiation (a) MRI at 2.5 months, (b) MRI at 4.5 months (c) MRI at 5.5 months](SNI-7-130-g009){#F3}

![T2 weighted series. Pictorial summary concerning follow up of edema from first day of treatment. Substantial amount of underlying edema at the first day of treatment (a) resolving 2.5 months after treatment (b). MRI at 5.5 months show new development of edema indication a radiation induced local reaction (c). MRI at 12 months displays reduction of perifocal edema suggesting the adverse reaction is once again resolving (d)](SNI-7-130-g010){#F4}

An FDG-PET at 5.5 months after treatment was thus performed (follow-up FDG-PET number 1) showing limited local uptake, confirming our suspicions of a local radiation adverse reaction \[[Figure 5](#F5){ref-type="fig"}\] without underlying tumor activity. The patient remained in good condition by this time \[[Table 7](#T7){ref-type="table"}\] and had ongoing systemic therapy. Prophylactic steroids were given prior each systemic treatment.

![FDG-PET at 5.5 months at the level of the pons (left), co-registered with MRI -- T1 weighted image with gadolinium at 5.5 months (center) and MRI T1 weighted FSPGR image with gadolinium (right). Decreased uptake on FDG-PET, confirming local radiation adverse effect](SNI-7-130-g011){#F5}

###### 

Clinical impact after AHR-GK (including follow-ups at 1, 2.5, 4.5, 5.5 months
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Follow-up MRI 8, 9, 10 months after radiosurgery (follow-up MRI numbers 5, 6, 7) showed stable conditions with no further brainstem tumor volume progression or supplementary edema. A new MRI taken at 12 months described a light depletion of local contrast enhancement, tumor volume, and adjacent edema \[[Figure 6](#F6){ref-type="fig"}\]. Follow-up FDG-PET (number 2) performed in December 2014 (13 months after AHR-GK) confirmed the absence of viable tumor \[[Figure 7](#F7){ref-type="fig"}\].

![MRI at 12 months: T1 weighted series revealing slight decrease in volume and contrast enhancement](SNI-7-130-g013){#F6}

![FDG-PET and co-registered contrast enhanced T1 weighted image at 12 months (right group): Tumor to contralateral normal frontal gray matter ratio still \<1 with no signs of viable tumor compared to FDG-PET from whole body PET (delayed phase) and co-registered contrast enhanced T1 weighted image at 5.5 months (left group)](SNI-7-130-g014){#F7}

The patient suffered a major primary tumor progression in June 2014. Because of low tolerance/growing resistance to systemic treatment, the patient developed further distant metastatic disease including new brain metastases. Between April and November 2014, a total of 40 new metastases were successively treated by single fraction \[[Figure 8](#F8){ref-type="fig"}\]. Mean doses to brain and brainstem axis corresponding to each separate GK intervention were judged acceptable \[Tables [8](#T8){ref-type="table"} and [9](#T9){ref-type="table"}\].

![LGP (Leksell GammaPlan^®^) software 3D summary of all stereotactic treated brain metastases between November 2014 and November 2015](SNI-7-130-g015){#F8}

###### 

LGP (Leksell GammaPlan^®^) dose estimations on Total Brain Volume (TBV - 1319 cc), corresponding to each Gamma Knife session (GK nr) between November 2013 and November 2014. Minimum (Min), maximum (Max) and mean radiation values are given in Gray Unit (Gy)
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###### 

LGP (Leksell GammaPlan^®^) based brainstem dose estimations corresponding to each Gamma Knife session (GK nr) between November 2013 and November 2014. Minimum (Min), maximum (Max) and mean radiation dose values are given in Gray Unit (Gy). Estimations corresponding to AHR- GK treatments 1 to 3 are based on a 'normal' brainstem tissue volume (pons metastasis not included)\* Dose estimations corresponding to treatments 4,5,6,7 are based on a total brainstem Volume comprehending healthy brainstem tissues and the previously treated pons metastasis (both components were regarded by that time as same organ at risk)\*\*
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Unfortunately, a CT-scan performed by late November 2014 showed additional thoracic and skeletal disease despite different anti-tumoral regimens. By that time, main clinical issues were described as fatigue and skin rash mainly due to systemic therapy (Karnofsky 70, RPA 3). No major neurological deficit or cognitive impairment was described at this stage. The brainstem metastasis remained inactive. Failing systemic treatment, the patient died in early February 2015.

DISCUSSION {#sec1-4}
==========

The brainstem is a highly eloquent organ with special architectural traits and complex neurophysiological functions. Although brainstem metastases account for only 5% of all intracranial metastases, these cases are usually difficult to manage because of its critical localization, often leading to significant neurological impairment. At present, there is no consensus on the optimal approach to treat these malignant neoplasms, especially in the case of local recurrence after radiation treatments such as WBRT. The role of radiosurgery in the treatment of smaller brainstem metastases has been well described in the last few years\[[@ref14][@ref18][@ref20][@ref22][@ref23][@ref24][@ref25][@ref27][@ref28][@ref29][@ref30][@ref31][@ref42][@ref43][@ref54][@ref55][@ref57]\] yet, the radiosurgical management of larger lesions remains difficult mainly due to dose-volume-related toxicity issues and clinical restrictions associated to overall metastatic activity. Hypofractionated regimens have proved effective in the management of brain malignancies in high- and low-risk areas.\[[@ref11][@ref20][@ref21][@ref35][@ref36][@ref47][@ref52][@ref58]\] Furthermore, the role of radiotherapy in the management of NSCLC has been widely documented.\[[@ref2][@ref3][@ref9][@ref12][@ref33][@ref35][@ref45]\] Understanding the relation between dose-volume values, clinical data, and local anatomical traits remains critical in terms of achieving local tumor control and avoiding/limiting normal tissue toxicity.

World medical literature\[[@ref5][@ref7][@ref14][@ref19][@ref20][@ref23][@ref25][@ref30][@ref32][@ref37][@ref43][@ref54][@ref57]\] has described a number of factors playing a potential role in the outcome of brainstem radiotherapy, foremost tumor volume, total irradiated brainstem volume, prescription (marginal) dose/fractionation model, histological traits (radiosensitive tumors, nonmelanoma and nonrenal cell histology), intracranial metastatic activity, and clinical status prior to treatment (Karnofsky/RPA). Co-morbidity is also likely to influence the outcome of radiosurgery. A study conducted by Debus *et al*. on brainstem tolerance to high dose conformal radiotherapy of skull base tumors (1997), exposed a number of predisposing factors that could potentially lower brainstem tolerance, among others diabetes, high blood pressure and prior skull surgeries.\[[@ref1][@ref55][@ref59]\] The above is worth serious analysis when considering the possible impact vascular co-morbidity might have on the mechanisms behind radiation-induced micro-environmental re-oxygenation and subsequent tumor tissue radio-sensitization.\[[@ref8][@ref26][@ref38][@ref44]\] However, reservation should be made to the fact that reoxygenation is more likely to occur in longer fractionated regimens (as in the case of conventional radiotherapy). In the case of hypofractionation (3--5 fractions according to own institutional standards), it is unclear if high dose per fraction still induces re-oxygenation or simply overcomes hypoxic tissue thresholds. More studies are necessary to elucidate these subjects.

Early studies promptly identified the relationship between prescription dose and irradiated brainstem volume in terms of toxicity. In the present day, the entire brainstem axis is known to have a radiation tolerance of up to 54 Gy using conventional fractionation of 1.8--2.0 Gy/day. Smaller volumes (up to 10 cc) may be treated to maximum doses of up to 59 Gy for conventional fractionation.\[[@ref37]\] Doses above 64 Gy seem to increase the risk of local toxicity; volume dependence beyond this point remains unclear.\[[@ref37]\]

When considering the average brainstem volume in the adult,\[[@ref10][@ref34]\] the above could lead to believe (though with much prudence), that approximately one-third (1/3) of the brainstem\'s total volume could be treated with doses aiming to 60 Gy with limited risk for local toxicity. In this particular case, the entire brainstem axis (including the metastasis) had an estimated volume of about 39 cc. Dose distributions to the brainstem after each radiosurgery are described in [Table 9](#T9){ref-type="table"}.

Our institutional experience in single fraction treatments supports the importance of dose-volume relations. the risk of local adverse events following a single treatment of intrinsic or adjacent brainstem tumors remains acceptable as long as its correspondent 10 Gy volume (to the brainstem) is kept within the 3 cc\'s circumscription. Furthermore, in day-to-day clinical practice, we stand somewhat close to Radiation Therapy Oncology Group (ROTG) 90--05 dose-volume recommendations of 24, 18, and 15 Gy for metastatic lesions of diameter \<20, 21--30, and 31--40 mm, respectively.\[[@ref46][@ref48][@ref49]\]

Extrapolating all of the above information onto a practical hypofractionated regimen dealing with local tumor control and restrained local toxicity is a matter of much debate nowadays, particularly facing inhomogeneous dose distributions. It is still highly dependent on the radiosurgical team\'s consensus on available mathematical/radiobiological models and subsequent isoeffective dose estimations/conversions.\[[@ref1][@ref4][@ref13][@ref41][@ref46][@ref50]\]

In our case, major challenges proved to be previous WBRT as well as underlying (and somehow cortisone-resistant) edema, theoretically increasing the risk for local toxicity, hence limiting radiation delivery. Considering the above, it was of outmost importance to prescribe a peripheral dosage able to "cumulate" as much radiation as possible within tumor bed boundaries (especially to contrast enhancing areas) while keeping radiation dissipation outside target as low and homogeneous as possible \[[Table 5](#T5){ref-type="table"}\]. The presence of edema remains an interesting subject of discussion; as pointed out earlier, it is generally believed to increase the risk for local radiation adverse events. According to our clinical experience, its presence (even somewhat extensive), does not necessarily correlate with later development of serious neurological deficit. Surrounding edema should be taken into consideration when deciding over a fractionation regimen but its presence should not necessarily hinder treatment as long as the patient\'s general condition remains acceptable and all underlying relevant factors have been taken into consideration.

Moreover, we believe RPA classes (among other prognostic classifications not mentioned in this paper) play a major predictive roll in the outcome of brain radiosurgery, especially in eloquent regions because of the likelihood of better response, we recommend the above technique to be limited to patients with RPA--classes 1 and 2.\[[@ref16][@ref17][@ref28][@ref39][@ref56]\]

Finally, much can be debated on the role the tumor\'s own radio-sensitivity and prior given WBRT played in the treatment\'s positive outcome was AHR-GK a "boost" procedure as such? Could comparable results, in similar conditions, be achieved when facing radio-resistant histologies? The latter will be the main subject of another paper.

CONCLUSION {#sec1-5}
==========

In terms of local tumor control and radiation tolerance, GK-based AHR-GK could be seen as an alternative neurosurgical approach in the management of large brain metastases in critical areas. Further studies into brainstem toxicity are required to improve the radio-therapeutics involved in these cases. Hypofractionation regimens should be individually assessed by means of imaging, relevant clinical information, dose-volume data, and the surgical team\'s commodity to work with available mathematical/radiobiological models.
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